Suzuoki Masato, Hida Yasuhiro, Miyamoto Masaki, Oshikiri Taro, Hiraoka Kei, Nakakubo Yoshihiro, Shinohara Toshiya, Itoh Tomoo, Okushiba Shunichi, Kondo Satoshi, Katoh Hiroyuki
Department of Surgical Oncology, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan.
Ann Surg Oncol. 2002 May;9(4):388-93. doi: 10.1007/BF02573874.
RCAS1 (receptor-binding cancer antigen expressed on SiSo cells) is a cancer cell-surface antigen and has been identified as a prognostic factor in several cancers. It is thought that tumor cells escape from immune attack by expressing RCAS1, which induces apoptosis in receptor-positive immune cells. We investigated the relationship between RCAS1 expression and clinicopathologic features and clinical outcome in patients with extrahepatic bile duct carcinoma (EBDC) who underwent curative resection.
RCAS1 expression was determined by immunohistochemistry in 60 patients with EBDC who underwent curative resection from 1992 to 1999. The patients were divided into two groups on the basis of the extent of RCAS1 expression: a low-expression group (immunoreactivity in <25% of cells) and a high-expression group. Expression was correlated with clinicopathologic features and prognosis.
RCAS1 was expressed in 52 (86.7%) of 60 tumors and at a high frequency in all histopathologic stages. High expression of RCAS1 was detected in 46 (76.7%) of 60 cases. No correlation existed between the pattern of RCAS1 expression and any clinicopathologic feature, although high expression did correlate with poor prognosis. High RCAS1 expression was an independent negative predictor for survival.
RCAS1 expression predicts poor outcome in resectable EBDC.
RCAS1（SiSo细胞上表达的受体结合癌抗原）是一种癌细胞表面抗原，已被确定为多种癌症的预后因素。据认为，肿瘤细胞通过表达RCAS1逃避免疫攻击，RCAS1可诱导受体阳性免疫细胞凋亡。我们研究了接受根治性切除的肝外胆管癌（EBDC）患者中RCAS1表达与临床病理特征及临床结局之间的关系。
采用免疫组织化学法检测了1992年至1999年间接受根治性切除的60例EBDC患者的RCAS1表达。根据RCAS1表达程度将患者分为两组：低表达组（<25%的细胞具有免疫反应性）和高表达组。将表达情况与临床病理特征及预后进行关联分析。
60例肿瘤中有52例（86.7%）表达RCAS1，且在所有组织病理学分期中表达频率均较高。60例中有46例（76.7%）检测到RCAS1高表达。RCAS1表达模式与任何临床病理特征均无相关性，尽管高表达与预后不良相关。RCAS1高表达是生存的独立负性预测因素。
RCAS1表达可预测可切除EBDC的不良预后。
